XM无法为美国居民提供服务。
S
S

Sanofi


市场新闻

Amgen falls as Truist downgrades to 'hold' on competition for experimental skin disease drug

BUZZ-Amgen falls as Truist downgrades to 'hold' on competition for experimental skin disease drug ** Shares of drugmaker Amgen AMGN.O fall 1% to $324.95 ** Truist Securities downgrades stock to "hold" from "buy", citing "extremely competitive" landscape for an experimental drug to treat atopic dermatitis or eczema ** Brokerage also raises PT to $33
A
R
S

France seeks job guarantees from Sanofi over Doliprane painkiller production

UPDATE 1-France seeks job guarantees from Sanofi over Doliprane painkiller production Adds quotes, details, background throughout PARIS, Oct 14 (Reuters) - The French government needs guarantees from drugmaker Sanofi SASY.PA that production of its popular Doliprane painkiller will stay in France to allow the sale of its consumer health branch to go ahead, Economy Minister Antoine Armand said on Monday.
S

French government seeking job guarantees from Sanofi over Doliprane production sites

French government seeking job guarantees from Sanofi over Doliprane production sites PARIS, Oct 14 (Reuters) - The French government is seeking job guarantees from drugmaker Sanofi SASY.PA regarding its Doliprane production sites in the event of a sale of its consumer health branch, Economy Minister Antoine Armand said on Monday. On Friday, Sanofi said it had entered talks to sell a controlling 50% stake in its Opella business - whose brands include Doliprane - to U.S.
S

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: CVS, Frasers Group, Tetragon, Oct 11 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday: * * CVS Health CVS.N is exiting its core infusion services business and plans to either close or sell 29 related regional pharmacies in the coming months, a company spokesperson confirmed to Reuters on Friday.
A
A
B
S
U

US FDA approves Pfizer's drug for rare bleeding disorder

UPDATE 2-US FDA approves Pfizer's drug for rare bleeding disorder Adds analyst estimates in paragraph 6, trial details in paragraph 8, and other treatments in paragraph 5, 10 and 11 By Sruthi Narasimha Chari and Christy Santhosh Oct 11 (Reuters) - The U.S. Food and Drug Administration approved Pfizer's PFE.N once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.
B
P
S

US FDA approves Pfizer's drug for rare bleeding disorder

US FDA approves Pfizer's drug for rare bleeding disorder Oct 11 (Reuters) - The U.S. Food and Drug Administration approved Pfizer's PFE.N once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday. Reporting by Sruthi Narasimha Chari and Christy Santhosh in Bengaluru; Editing by Vijay Kish
B
P
S

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Updates: Nippon Steel Oct 11 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Friday: ** Nippon Steel 5401.T said it will sell its entire 50% stake in a joint-venture steel plant it has in Calvert, Alabama, with ArcelorMittal MT.LU , if the top Japanese steelmaker succeeds in a buyout bid for United States Steel X.N .
A
A
B
S
U

Direct lenders’ golden moment is over

RPT-BREAKINGVIEWS-Direct lenders’ golden moment is over The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Jonathan Guilford and Neil Unmack NEW YORK, Oct 10 (Reuters Breakingviews) - The downside of having a “golden moment” is that things can only get worse. That’s what direct lenders, or the core of the private-credit world that focuses on buyout debt, are finding little more than a year after Blackstone BX.N President Jon Gray pronounced a heyday f
A
B
C
J
S

Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India

Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India Novo to double global process leaders in India in 3-4 years Novo has partnered with 10 Indian AI start-ups for various tasks India centre to mirror Denmark HQ in handling R&D data, exec says Other drugmakers ramping up operations in India as well By Rishika Sadam and Haripriya Suresh BENGALURU, Oct 11 (Reuters) - Novo Nordisk NOVOb.CO , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolst
S

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Oct 11 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Friday: ** Sanofi SASY.PA has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical group said.
A
A
B
S
U

CD&R is a "serious" investment fund, says French finance ministry

CD&R is a "serious" investment fund, says French finance ministry PARIS, Oct 11 (Reuters) - France considers that U.S. private equity firm Clayton Dubilier & Rice (CD&R) is a "serious" investment fund with a positive outlook for the global development of Sanofi's SASY.PA consumer health business Opella and Opella's plants in France, said the country's finance ministry.
S

Sanofi in talks to sell 50% stake in consumer health business to CD&R

UPDATE 2-Sanofi in talks to sell 50% stake in consumer health business to CD&R Adds French finance ministry comments in paragraphs 7-9 PARIS, Oct 11 (Reuters) - Sanofi SASY.PA has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical group said on Friday.
P
S

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Oct 11 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. FRENCH BUDGET: France's government delivered its 2025 budget on Thursday with plans for 60 billion euros ($65.68 billion) worth of spending cuts and tax hikes on the wealthy and big companies to tackle a spiralling fiscal deficit.
S
F
N
U

CD&R nears deal to buy Sanofi's consumer unit for $16 bln, source says

UPDATE 1-CD&R nears deal to buy Sanofi's consumer unit for $16 bln, source says Changes sourcing in paragraph 1 By Dominique Patton Oct 10 (Reuters) - Sanofi SASY.PA is closing in on a deal to sell its consumer health unit for about 15 billion euros ($16.4 billion) to U.S. private equity firm Clayton Dubilier & Rice (CD&R) , a person familiar with the matter told Reuters.
S

Denali-Sanofi scraps mid-stage study for multiple sclerosis drug

UPDATE 1-Denali-Sanofi scraps mid-stage study for multiple sclerosis drug Adds background throughout Oct 10 (Reuters) - Denali Therapeutics DNLI.O said on Thursday its partner Sanofi SASY.PA has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary study goals. Multiple sclerosis is a debilitating neurological condition where the immune system degrades the protective covering of nerves.
S

CD&R nears deal to buy Sanofi's consumer unit for $16 bln, Bloomberg News reports

CD&R nears deal to buy Sanofi's consumer unit for $16 bln, Bloomberg News reports Oct 10 (Reuters) - Private equity firm Clayton Dubilier & Rice (CD&R) is nearing a deal to acquire Sanofi's SASY.PA consumer health unit for about 15 billion euros ($16.4 billion), Bloomberg News reported on Thursday. Sanofi has been planning to spin off or sell its consumer unit to shore up new drug development spending at its core business.
S

CD&R Nears €15 Billion Deal For Sanofi Consumer Health Unit- Bloomberg News

BRIEF-CD&R Nears €15 Billion Deal For Sanofi Consumer Health Unit- Bloomberg News Oct 10 (Reuters) - CD&R NEARS €15 BILLION DEAL FOR SANOFI CONSUMER HEALTH UNIT- BLOOMBERG NEWS Source text: https://tinyurl.com/ycy3ewzw Further company coverage: SASY.PA
S

Denali-Sanofi scraps mid-stage study for multiple sclerosis drug

Denali-Sanofi scraps mid-stage study for multiple sclerosis drug Oct 10 (Reuters) - Drug developer Denali Therapeutics DNLI.O said on Thursday its partner Sanofi SASY.PA has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary goals. Reporting by Mariam Sunny in Benga
S

French company EUROAPI completes financing for its strategic plan

BRIEF-French company EUROAPI completes financing for its strategic plan Oct 10 (Reuters) - Euroapi Sa EAPI.PA : EUR 451M REVOLVING CREDIT FACILITY REFINANCED WITH A MATURITY EXTENDED TO FEBRUARY 2029 ISSUANCE OF A EUR 200M PERPETUAL DEEPLY SUBORDINATED HYBRID BOND SUBSCRIBED BY SANOFI EUR 54M PRODUCT CAPACITY RESERVATION FOR FIVE PRODUCTS AND FURTH
S

Direct lenders’ golden moment is over

BREAKINGVIEWS-Direct lenders’ golden moment is over The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Jonathan Guilford and Neil Unmack NEW YORK, Oct 10 (Reuters Breakingviews) - The downside of having a “golden moment” is that things can only get worse. That’s what direct lenders, or the core of the private-credit world that focuses on buyout debt, are finding little more than a year after Blackstone BX.N President Jon Gray pronounced a heyday for n
A
B
C
J
S



商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明